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Abstract
Background: Restriction of dietary sodium is routinely recommended for patients with chronic kidney disease
(CKD). Whether or not sodium intake is associated with the progression of CKD and mortality remains controversial.
We evaluated the association of urinary sodium excretion (as a surrogate for sodium intake) on the need for renal
replacement therapy and mortality in patients with advanced CKD.
Methods: We conducted a retrospective study of patients followed at a CKD clinic of a tertiary care hospital from
January 2010 to December 2012. Adult patients with advanced CKD (estimated glomerular filtration rate (eGFR)
<30 ml/min/1.73 m2) were included. Using a time-to-event analysis, we examined the association of urinary sodium
excretion as a continuous and also as a categorical variable (categorized as low sodium diet - LSD (<100 mEq/day),
medium sodium diet - MSD (100–150 mEq/day), and high sodium diet - HSD (>150 mEq/day) and the outcomes of
interest. The primary outcome was defined as composite of progression to end-stage renal disease requiring any
type of renal replacement therapy and mortality. The secondary outcome was change in eGFR/year.
Results: 341 patients (82 LSD, 116 MSD and 143 HSD) were included in the study (mean follow up of 1.5 years)
with a mean eGFR decline of 2.7 ml/min/1.73 m2/year. 105 patients (31 %) required renal replacement therapy and
10 (3 %) died. There was no association between urinary sodium excretion and change in the eGFR or need for
renal replacement therapy and mortality in crude or adjusted models (unadjusted HR 1.002; 95%CI 1.000–1.004,
adjusted HR 1.001; 95%CI 0.998–1.004).
Conclusion: In patients with advanced CKD (eGFR < 30 ml/min/1.73 m2), sodium intake does not appear to impact
the progression of CKD to end-stage renal disease; however, more definitive studies are needed.
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Background
Patients with chronic kidney disease (CKD) have a sig-
nificantly higher mortality compared to the general
population and this increases as the estimated glomeru-
lar filtration rate (eGFR) declines [1]. Thus, preservation
of kidney function and avoidance of end-stage renal dis-
ease (ESRD) is a key therapeutic target. Among the rec-
ommendations for preservation of kidney function is the
control of dietary sodium as a modifiable risk factor.
Recent international guidelines have incorporated so-
dium restriction into their recommendations. Kidney
Disease Improving Global Outcomes (KDIGO) suggests
a reduction to <2 g/day of sodium which corresponds to
5 g/day of salt for adult patients with CKD [2]. These
recommendations are based on low level evidence from
studies with marked heterogeneity [3], although the re-
sults overall suggest that modest sodium restriction
should be beneficial for patients with CKD. However,
there is a paucity of studies specifically addressing the
effect of sodium intake in patients with advanced CKD
(defined as eGFR < 30 ml/min/1.73 m2). Studies that in-
cluded individuals with advanced CKD have been limited
by surrogate short-term outcomes or inclusion of non-
diabetic patients [4–6]. As such, in patients with ad-
vanced CKD, it remains unknown whether alterations in
sodium intake impact clinically relevant outcomes, such
as mortality, CKD progression and the need for dialysis.
The aim of our study was to determine if urinary so-
dium excretion is associated with mortality and need for
renal replacement therapy in patients with advanced
CKD. We hypothesized that higher levels of urinary so-
dium excretion (used as a surrogate for sodium intake)
would be associated with adverse clinical outcomes.
Methods
Patient population and measurements
This is a retrospective cohort study using prospectively
collected data on adult patients (>18 years) followed in
the progressive renal insufficiency clinic at The Ottawa
Hospital, a 1,150 bed academic tertiary care center serv-
ing a population of approximately 1.2 million, located in
Ontario, Canada. The progressive renal insufficiency
clinic is a specialty multi-disciplinary care clinic in the
CKD program for patients approaching ESRD. Patients
with progressive kidney disease are referred to this clinic
at the discretion of primary nephrologist in anticipation
of needing renal replacement therapy. Attempts are
made to collect 24 h urine for sodium excretion at least
twice per year. Standardised instructions are given to
each patient for collection of 24 h urine.
The study included patients with eGFR < 30 ml/min/
1.73 m2 calculated by the 4 variable MDRD formula [7],
with at least two visits to the clinic and at least one 24-h
urine sodium excretion (USE) measurement between
January 2010 and December 2012. Patients who required
any kind of renal replacement therapy prior to the sec-
ond visit were excluded. The date of first visit was
deemed the date of study entry.
Data collection
Data on all patients were obtained through the clinic’s
comprehensive database since its inception in January
1st, 2010. The accuracy of the data in the database is
verified every six months by auditing 5 % of entries and
accuracy has been > 95 %. Data collected included age,
gender, blood pressure (BP), body-mass index (BMI),
eGFR, urine excretion of sodium, protein and creatinine,
cause of CKD, comorbidities, medications, date of death
and date of dialysis start or renal transplantation. Blood
pressure was measured in sitting position after at least
five minutes of rest. Mean arterial blood pressure (MAP)
was calculated using the formula: MAP = 2/3 diastolic
BP + 1/3 systolic BP. Urine sodium, urine creatinine and
urine protein were all measured on the Siemens Vista
1500 analyzer using manufacturers’ reagents. If 24- h
urine protein was not available, spot urine protein to
creatinine ratios were converted to 24 h urine protein
excretion [8].
Blood pressure, eGFR and proteinuria were measured
at each clinic visit. 24-h USE was performed periodically
to monitor compliance and assist in counseling patients
regarding sodium restriction.
Sodium intake for each patient was estimated from the
average 24-h USE measured during the follow-up period.
In order to account for inappropriate collection of 24-h
urine, 24-h urine sodium excretion was corrected for ex-
pected creatinine excretion. Expected creatinine excre-
tion was calculated by the following formulas: If male
then creatinine excretion (mmol/day) = (28.2−(0.172*age))*
0.00884*weight (Kg); if female then creatinine excretion
(mmol/day) = (21.9−(0.115*age))* 0.00884*weight (Kg) [9].
A priori, we categorized the patients according to their
mean 24-h USE into three groups: low sodium diet (LSD)
-USE < 100 mEq/day, medium sodium diet (MSD) - USE
100–150 mEq/day and high sodium diet (HSD) - USE >
150 mEq/day. We selected these cut-off points first, to de-
termine whether patients with advanced CKD have higher
mortality or faster progression of CKD if their sodium in-
take is higher than currently recommended (>100 mEq/
day), and second, to investigate whether daily sodium in-
take between 100 and 150 mEq (which is simpler to achieve
than <100 mEq/day for most patients) is associated with
different outcomes compared to LSD and HSD.
Outcomes
The primary outcome was a composite of progression to
ESRD requiring any type of renal replacement therapy
(dialysis or renal transplant) and mortality.
Mazarova et al. BMC Nephrology  (2016) 17:123 Page 2 of 7
The secondary outcome was the decline in eGFR in
ml/min/1.73 m2 per year.
Statistical analyses
Continuous variables are reported as mean (± SD) and
categorical variables are reported as numbers and per-
centages. Analysis of variance with Tukey correction was
used to compare continuous variables. If Levene's test
for equality of error variances was positive, the data was
log transformed. Chi squared test was used to compare
categorical variables. Time-to-event analyses were con-
ducted using the Kaplan-Meier (KM) method and Cox
proportional hazards. The log rank test was used with
the KM method to assess for statistical significance. To
better quantify individual sodium exposure and account
for within person data variability, sodium intake was
modeled continuously using time-dependent Cox
models using the mean 24-h urine sodium excretion. Po-
tential confounders included in the Cox models were
sex, age, baseline eGFR, mean arterial blood pressure
(MAP), body mass index (BMI), diabetes, log trans-
formed 24-h proteinuria, and renin-angiotensin system
(RAS) blockers (angiotensin converting enzyme inhibi-
tors and angiotensin receptor blockers) use. MAP and
log transformed 24-h proteinuria were treated as time
dependent variables, and changes in their values over
time were incorporated into the adjusted Cox analyses.
Sensitivity analysis was performed for sodium uncor-
rected for expected creatinine excretion as well as after
censoring for death.
All statistical analyses were performed using SAS soft-
ware (Version 9.3) and Medcalc (Version 13.2). P < 0.05
was considered statistically significant.
Results
Baseline characteristics
The baseline characteristics of the study cohort are pre-
sented in Table 1. Three hundred forty-one patients
were included with a mean age of 64.4 years. Most pa-
tients were male (62.5 %) and had an elevated BMI
(30 kg/m2). At baseline, MAP was 111 mmHg and the
mean eGFR was 17.1 ml/min/1.73 m2. The most com-
mon cause of CKD was diabetic nephropathy. The ma-
jority of patients were hypertensive and diabetic (94 %
and 58 % respectively). 53 % were on RAS blockade.
Based on the mean USE during the observational
period, 82, 116, and 143 patients were categorized into
low sodium diet (LSD; USE < 100 mEq/day), medium so-
dium diet (MSD; USE 100–150 mEq/day), and high
sodium diet (HSD; USE > 150 mEq/day) groups, respect-
ively. At baseline, the three groups did not differ in gen-
der, MAP, eGFR, or use of diuretics and RAS blockers.
Patients from the HSD group were younger (mean age
60 years) with a higher BMI (33.7 kg/m2) and were more
proteinuric. The variability in sodium excretion in pa-
tients with more than one 24-h urine collection was
assessed by intra-individual coefficient of variation (CV)
defined as SD/Mean. The CV for the whole group was
55 %. We also assessed variability in sodium excretion
by dividing patients into two groups by median of base-
line eGFR and found that CV for the higher eGFR group
was 56 % and for the lower eGFR group it was 53 % in-
dicating similar variability in sodium excretion in the
two groups.
Sodium diet groups and outcomes
The mean follow-up time was 1.5 years. The average
number of 24-h USE measurements per patient was 3.6
(±2.0). 54 patients had only one sodium measurement.
The three groups differed in mean USE as expected (P <
0.01), however, there was no significant difference in
eGFR decline, RRT requirement or death (Table 2). A
sensitivity analysis comparing LSD to all other patients
also did not reveal a statistically significant difference;
(Additional file 1 and 2). A sensitivity analysis using
CKD-EPI eGFR also did not change the results
(Additional file 3).
Time-to-event (ESRD + death) analyses
Of the 115 patients (34 %) who reached the primary out-
come (105 reached ESRD and 10 died), 25 (31 %) were
from the LSD group, 38 (33 %) from the MSD group,
and 52 (36 %) from the HSD group (Table 2). The me-
dian time to RRT and death among the three groups was
21 months (95 % CI, 18.3–25) and it did not differ sig-
nificantly (Log rank test; P = 0.73; Fig. 1).
In the unadjusted Cox analysis that modeled USE as a
continuous variable, increase in USE was not signifi-
cantly associated with an excess risk of progression to
ESRD and mortality (HR 1.002; 95 % CI 1.000–1.004;
(Table 3). After adjusting for age, sex, baseline eGFR,
MAP, proteinuria, diabetes, BMI, and RAS blockers, the
hazard ratio for need for RRT and mortality did not
change (Table 3). A sensitivity analyses conducted after
censoring death did not change the results (Additional
file 4). A second sensitivity analysis conducted with
sodium excretion uncorrected for expected creatinine ex-
cretion also did not change the results (Additional file 5).
Since MAP is likely to be on the causal pathway for the
association between sodium and renal outcomes, we did
another sensitivity analysis by excluding MAP from the
Cox model for primary outcome and results did not
change significantly (Additional file 6).
Discussion
In this retrospective cohort study of 341 patients with
advanced CKD, we did not find an association between
urinary sodium excretion (USE) and combined outcome
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of mortality and need for renal replacement therapy
(RRT) or eGFR decline. Patients with high USE were
more likely to be younger, had higher BMI, and were
more proteinuric. There was no association between
need for RRT and the mean USE as a categorical or con-
tinuous variable. Furthermore, there was no association
between USE and the eGFR decline. Our study suggests
USE (a surrogate for dietary sodium) may not play a
significant role in the progression of CKD to end-stage
renal disease in patients with severe kidney disease. To
our knowledge, this is the first report on the association
of USE on the need for renal replacement therapy and
eGFR declines in a diverse CKD population with eGFR
< 30 ml/min/1.73 m2.
There are no randomized control trials (RCTs) exam-
ining sodium intake and long-term renal outcomes, such
Table 2 Cohort characteristics at the end of follow-up
All LSD MSD HSD P value
Duration of F/U years, mean (SD) 1.5 (0.91) 1.5 (0.88) 1.6 (0.91) 1.47 (0.93) 0.54
α24-h USE mEq/day, mean (SD) 156 (86) 79 (23) 124 (31) 222 (87) <0.01
Change in eGFR/year, ml/min/1.73 m2; mean (SD) 2.7 (5.0) 2.51 (5.2) 3.36 (5.5) 3.33 (6.4) 0.55
ESRD n (%) 105 (30.8) 22 (26.8) 35 (30.2) 48 (33.6) 0.74
Deaths n (%) 10 (2.9) 3 (3.7) 3 (2.6) 4 (2.8) 0.91
SD standard deviation, F/U follow-up, USE urinary sodium excretion, eGFR estimated glomerular filtration rate, ESRD end stage renal disease
αCorrected for creatinine excretion
Table 1 Baseline characteristics
All N = 341 LSD N = 82 MSD N = 116 HSD N = 143 P value
Age years, mean (SD) 64.4 (14.9) 68.4 (15.1) β 66.9 (15.4) 60.1 (13.2)μ <0.05
Female, n (%) 128 (37.5) 35 (42.7) 46 (39.7) 47 (32.9) 0.29
MAP mm Hg, mean (SD) 111 (14.2) 111 (14.1) 114 (15.1) 112 (13.5) 0.36
BMI kg/m2, mean (SD) 29.9 (6.6) 25.3 (4.1) α, β 28.6 (4.8) μ, 33.7 (7.0) <0.05
eGFR ml/min/1.73 m2 mean, (SD) 17.1 (5.5) 16.4 (4.1) 18.0 (6.7) 16.7 (5.2) 0.30
Urine protein, g/day median, (IQR) 1.5 (2.7) 1.0 (2.1) α, β 1.3 (1.9) 1.9 (3.4) <0.05
Cause of CKD, n (%)
Diabetic nephropathy 162 (47.5) 27 (32.9) 50 (43.1) 85 (59.4) 0.06
Ischemic nephropathy 61 (17.9) 21 (25,6) 21 (18.1) 19 (13.3) 0.16
Glomerulonephritis 43 (12.7) 14 (17.1) 16 (13.8) 13 (9.1) 0.29
PCKD 27 (8) 8 (9.6) 10 (8.6) 9 (6.3) 0.67
Other 48 (14.1) 12 (14.6) 19 (16.4) 17 (11.9) 0.66
Comorbidities, n (%)
Diabetes 198 (58.2) 32 (39) 61 (52.6) 105 (73.4) 0.02
CAD 105 (30.8) 20 (24.4) 35 (30.2) 50 (35.0) 0.48
CHF 79 (23.2) 13 (15.9) 22 (19) 44 (30.8) 0.08
Hypertension 319 (93.6) 76 (92.7) 109 (94) 134 (93.7) 0.99
CVA 36 (10.6) 7 (8.5) 12 (10.3) 17 (11.9) 0.78
Dyslilidemia 235 (68.9) 50 (61) 81 (69.8) 104 (72.7) 0.72
Medications, n (%)
RAS blocker 181 (53.1) 40 (48.8) 64 (55.2) 77 (53.9) 0.88
Diuretic 219 (64.2) 48 (58.5) 76 (65.5) 95 (66.4) 0.84
Calcium channel blockers 237 (69.5) 53 (64.6) 87 (75) 97 (67.8) 0.78
Beta blockers 178 (52.2) 38 (46.3) 62 (53.4) 78 (54.5) 0.78
SD standard deviation, IQR interquartile range, MAP mean arterial blood pressure, BMI body mass index, eGFR estimated glomerular filtration rate, PCKD polycystic
kidney disease, CAD coronary artery disease, CHF congestive heart failure, CVA cerebrovascular accident, RAS renin-angiotensin system
αP < 0.05 between LSD and MSD
βP < 0.05 between LSD and HSD
μP < 0.05 between MSD and HSD
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as progression of CKD or ESRD and thus most of the
evidence comes from observational studies. There are,
however, short-term RCTs showing a beneficial effect of
dietary sodium restriction on proteinuria and blood
pressure [6, 10]. This can suggest that lowering sodium
intake may slow down the eGFR decline and thus post-
pone dialysis initiation. The Modified Diet in Renal
Disease (MDRD) study that included 840 non-diabetic
patients with CKD (mean eGFR 32.5 ml/min/1.73 m2)
did not show any association between urine sodium and
kidney failure (which was defined as initiation of dialysis
or transplantation) or the composite outcome of renal
failure and all-cause mortality [5]. Neither a recent post
hoc analysis of the ONTARGET and TRANSCEND tri-
als revealed an association between sodium intake and
clinically important renal outcomes in patients with
cardio-vascular risk factors [11]. A limitation of these
two trials was that the sodium intake was estimated
from a spot morning urine sample using the Kawasaki
formula, however, the large sample size (28, 880 pa-
tients), international representation of the cohort and
completeness of data retrieval add considerable robust-
ness to the conclusions. A secondary analysis of the
REIN trials [12] involving 500 non-diabetic patients with
CKD (baseline creatinine clearance 42.5 ml/min) dem-
onstrated that each 100 mEq/g increase in urinary so-
dium/creatinine excretion was associated with a 1.61-
fold (95 % CI, 1.15–1.24) higher risk for ESRD. However,
after adjusting for baseline proteinuria this effect was
significantly attenuated to 1.38-fold (95 % CI; 0.95–2.00).
A recent study by McQuarrie et al [13] showed a similar
finding – they demonstrated an association between
USE and the risk of requiring RRT in CKD patients, but
this was not independent of albuminuria or baseline
eGFR.
More than half of the patients involved in our report
had diabetes. The Finn Diane study that followed 2,807
 Kaplan Meier Curve for Sodium groups adjusted for creatinine
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Fig. 1 Kaplan Meier Curve for Sodium Groups. The analysis did not show any difference in time to composite outcome (renal replacement
therapy + Death) among the three groups (P = 0.73)
Table 3 Cox model for primary outcome (renal replacement
therapy + death)
Hazard ratio 95 % CI P value
Unadjusted 1.002 1.000 – 1.004 0.07
Multivariable adjusted
Urinary sodium excretion 1.001 0.998 – 1.004 0.51
Age 1.005 0.992 – 1.018 0.47
Female 0.507 0.339 – 0.758 <0.01
Baseline eGFR 0.832 0.782 – 0.885 <0.01
MAP over time 1.005 0.992 – 1.018 0.45
Log proteinuria over time 1.646 1.325 – 2.045 <0.01
Diabetes 0.86 0.58 – 1.268 0.44
BMI 0.959 0.921 – 0.998 0.04
RAS blockers 0.839 0.569 – 1.236 0.37
MAP mean arterial blood pressure, RAS renin angiotensin system, BMI body
mass index
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type I diabetics with mean baseline eGFR > 80 ml/min/
1.73 m2 over 10 years, showed an inverse association of
urine sodium and ESRD – macroalbuminuric patients
with the lowest sodium excretion had the highest cumu-
lative incidence of ESRD. [14] The post-hoc analysis of
RENAAL and IDNT yielded different results [15]. The
authors reported a significantly lower risk for doubling
of serum creatinine or ESRD in the lowest tertile of so-
dium intake if the patients were on angiotensin receptor
blocker treatment, compared to the control group
treated with non-RAS antihypertensive agents. Of note,
sodium intake was not randomized and there were
significant differences in the study population character-
istics such as lower eGFR and higher urinary albumin-
to-creatinine ratio in the highest tertile of sodium intake
(for which the analysis was not adjusted).
In our CKD study population, 58 % of patients (LSD
and MSD group) had sodium intake within or close to
the recommended target with HSD group represented a
common salt intake of the general population in western
and particularly in Asian countries [16]. In spite of clear
separation of the groups, we did not find an effect of
lower sodium excretion resulting in less mortality and
need for ESRD. It is also possible that sodium intake
does not play a significant role in CKD progression once
renal disease is very advanced. Another possible factor is
salt sensitivity that as a mechanism may be different in
CKD populations to the general population. Finally,
marked dietary sodium restriction may have adverse con-
sequences, including activation of the sympathetic and
RAAS systems, reduction in insulin sensitivity, and in-
creased LDL cholesterol [17, 18]. Indeed, the relationship
between sodium intake and mortality in the general popu-
lation is J-curved [19], and it is possible that a similar rela-
tionship exists for renal disease progression; although the
nadir may vary in different patient populations.
Our study has two strengths: first, the data were ob-
tained from a CKD patient population who received treat-
ment based on current guidelines. Second, although it is
an observational study, the data was prospectively col-
lected and data entry was verified periodically with > 95 %
of data being accurate.
The major study limitation was short follow-up period.
Although there is a trend to more ESRD and faster GFR
decline with higher sodium intake, it is possible that
follow-up was not long enough to demonstrate statistically
significant impact on ESRD and GFR decline. The second
limitation is the observational nature of the study, thus
causal relationships cannot be discerned, and residual
confounding could impact the results. Although we calcu-
lated the average of urinary sodium excretion for each pa-
tient, the number of measurements per patient was low
(mean 3.4 USE measurements/patient), and therefore we
cannot account for changes in sodium intake that
occurred before or after urinary sodium testing. Moreover,
there are day-to-day variability in sodium intake and ex-
cretion [20], which may also affect the accuracy of sodium
intake estimation. The timing of initiating diuretics and
increasing their dose may also impact sodium excretion.
At our institution, diuretics are usually initiated (or dose
changed) at the visit and urine collection is done on a sub-
sequent visit thus minimizing the impact of change in di-
uretic dose on sodium excretion. In addition we could not
address the issue of mortality with high sodium intake be-
cause of low number of deaths in our population. Finally,
In our study RAS blockers were used more often in pa-
tients who were in the MSD and HSD group. Thus in our
study, overweight and diabetic patients would have bene-
fited less from RAS blockers.
Conclusion
In patients with eGFR < 30 ml/min/1.73 m2, sodium intake
did not affect progression of CKD to dialysis. Given the
limitations of our study outlined above, prospective stud-
ies are desirable to address the issue of appropriate coun-
seling for sodium intake in patients with advanced CKD.
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